Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

67.52 +3.91 (+6.14%)
Streaming Delayed Price Updated: 12:51 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 Next >
GeneDx Announces Completion of Fabric Genomics Acquisition
From GeneDx
Via Business Wire
GeneDx Reports First Quarter 2025 Financial Results and Business Highlights
From GeneDx
Via Business Wire
GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale
From GeneDx
Via Business Wire
GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025
From GeneDx
Via Business Wire
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication
From GeneDx
Via Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies
From GeneDx
Via Business Wire
GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting
From GeneDx
Via Business Wire
GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis
From GeneDx
Via Business Wire
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
From GeneDx
Via Business Wire
Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
From GeneDx
Via Business Wire
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
From GeneDx
Via Business Wire
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
From GeneDx
Via Business Wire
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
From GeneDx
Via Business Wire
GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
From GeneDx
Via Business Wire
GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
From GeneDx
Via Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
GeneDx Announces Preliminary 2024 Financial Results
From GeneDx
Via Business Wire
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
From GeneDx
Via Business Wire
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
From GeneDx
Via Business Wire
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
From GeneDx
Via Business Wire
GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From GeneDx
Via Business Wire
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
From GeneDx
Via Business Wire
GeneDx to Participate in Upcoming Investor Conference
From GeneDx
Via Business Wire
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
From GeneDx
Via Business Wire
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
From GeneDx
Via Business Wire
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
From GeneDx
Via Business Wire
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
From GeneDx
Via Business Wire
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
From GeneDx
Via Business Wire
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
From GeneDx
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.